{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:39:36Z","timestamp":1786451976839,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.urolonc.2012.01.016","type":"journal-article","created":{"date-parts":[[2012,3,4]],"date-time":"2012-03-04T05:14:37Z","timestamp":1330838077000},"page":"990-996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Two decades' experience with a prospective biobank for urologic oncology: research, clinical care, and the patients' view"],"prefix":"10.1016","volume":"31","author":[{"given":"Johannes","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Herpel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard","family":"Jakobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris A.","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Pahernik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hohenfellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2012.01.016_bib1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.urolonc.2010.03.012","article-title":"New concepts of biobanks\u2013strategic chance for uro-oncology","volume":"28","author":"Goebell","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2012.01.016_bib2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00428-010-0998-1","article-title":"Quality management and accreditation of research tissue banks: Experience of the National Center for Tumor Diseases (NCT) Heidelberg","volume":"457","author":"Herpel","year":"2010","journal-title":"Virchows Arch"},{"key":"10.1016\/j.urolonc.2012.01.016_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.urolonc.2012.01.016_bib4","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1464-410X.2008.08236.x","article-title":"Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: Possible prognostic differences","volume":"103","author":"Bedke","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2012.01.016_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.juro.2008.03.026","article-title":"Prognostic stratification of localized renal cell carcinoma by tumor size","volume":"180","author":"Bedke","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.016_bib6","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1464-410X.2006.06418.x","article-title":"Thoraco-abdominal approach to large retroperitoneal tumours","volume":"98","author":"Buse","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2012.01.016_bib7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00018-007-6510-7","article-title":"Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis","volume":"64","author":"Crnkovi\u0107-Mertens","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.urolonc.2012.01.016_bib8","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.juro.2007.01.039","article-title":"Renal cell carcinoma with tumor thrombus extension into the vena cava: Prospective long-term followup","volume":"177","author":"Haferkamp","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.016_bib9","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1464-410X.2008.07910.x","article-title":"High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma","volume":"102","author":"Haferkamp","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2012.01.016_bib10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1245\/s10434-009-0812-y","article-title":"Prognostic factors influencing long-term survival of patients undergoing nephron-sparing surgery for nonmetastatic renal-cell carcinoma (RCC) with imperative indications","volume":"17","author":"Haferkamp","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.urolonc.2012.01.016_bib11","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1464-410X.2007.07375.x","article-title":"The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy","volume":"101","author":"Haferkamp","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2012.01.016_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000321008","article-title":"Preoperative hydronephrosis predicts advanced bladder cancer but is not an independent factor for cancer-specific survival after radical cystectomy","volume":"86","author":"Hofner","year":"2011","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2012.01.016_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00345-010-0631-6","article-title":"PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: Impact on hemiablative focal therapy","volume":"30","author":"Hofner","year":"2012","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2012.01.016_bib14","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/j.1464-410X.2010.09345.x","article-title":"Risk factors and clinical management of haemorrhage after open nephron-sparing surgery","volume":"106","author":"Huber","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2012.01.016_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000322545","article-title":"Initial experience with Temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: Good clinical response","volume":"86","author":"Kuru","year":"2011","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2012.01.016_bib16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/1078-0432.CCR-08-0284","article-title":"Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer","volume":"15","author":"Macher-Goeppinger","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2012.01.016_bib17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1593\/neo.08626","article-title":"Decoy receptor 3 is a prognostic factor in renal cell cancer","volume":"10","author":"Macher-Goeppinger","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.urolonc.2012.01.016_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.canlet.2010.12.005","article-title":"Expression and prognostic relevance of the death receptor CD95 (Fas\/APO1) in renal cell carcinomas","volume":"301","author":"Macher-Goeppinger","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.urolonc.2012.01.016_bib19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/modpathol.2011.169","article-title":"Molecular heterogeneity of TFE3 activation in renal cell carcinomas","volume":"25","author":"Macher-Goeppinger","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2012.01.016_bib20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3109\/00365599.2011.621143","article-title":"Small renal cell carcinoma: Oncologic outcome with tumour size","volume":"45","author":"Pahernik","year":"2011","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.urolonc.2012.01.016_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00345-009-0414-0","article-title":"Survival in prostate cancer patients > or = 70 years after radical prostatectomy and comparison to younger patients","volume":"27","author":"Pfitzenmaier","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2012.01.016_bib22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1464-410X.2008.07791.x","article-title":"Positive surgical margins after radical prostatectomy: Do they have an impact on biochemical or clinical progression?","volume":"102","author":"Pfitzenmaier","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2012.01.016_bib23","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1464-410X.2008.08149.x","article-title":"Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?","volume":"103","author":"Pfitzenmaier","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2012.01.016_bib24","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/sj.bjc.6604028","article-title":"Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney","volume":"97","author":"Wagener","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2012.01.016_bib25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/ijc.23683","article-title":"The enhancer of zeste homologue 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells","volume":"123","author":"Wagener","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2012.01.016_bib26","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/1471-2407-10-524","article-title":"Enhancer of zeste homologue 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma","volume":"10","author":"Wagener","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2012.01.016_bib27","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1200\/JCO.2008.19.9406","article-title":"Quality of surveillance for stage I testis cancer in the community","volume":"27","author":"Yu","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.016_bib28","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/bmj.332.7540.544","article-title":"One-time general consent for research on biological samples","volume":"332","author":"Wendler","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2012.01.016_bib29","unstructured":"Huber J, Herpel E, Autschbach F, et al. Collection of biospecimen resources for cancer research: Ethical framework and acceptance from the patients' point of view, in Dabrock P, Taupitz J, Ried J (eds) Trust in biobanking: Dealing with ethical, legal and social issues in an emerging field of biotechnology. Berlin, Heidelberg: Springer; in press."},{"key":"10.1016\/j.urolonc.2012.01.016_bib30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jnci\/94.10.769","article-title":"High rate of consent to bank biologic samples for future research: The eastern cooperative Oncology Group experience","volume":"94","author":"Malone","year":"2002","journal-title":"J Natl Cancer Inst"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143912000464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143912000464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:14:06Z","timestamp":1786450446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143912000464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1078143912000464"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.01.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two decades' experience with a prospective biobank for urologic oncology: research, clinical care, and the patients' view","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}